<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> characterized by arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>, <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent abortions</z:e>, and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is possible to find patients with clinical signs of APS who persistently test negative for aPL (seronegative APS, or SN-APS) </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to identify new antigenic target(s) of autoantibodies in APS patients, which may also be recognized in SN-APS </plain></SENT>
<SENT sid="3" pm="."><plain>We tested sera from patients with SN-APS with a proteomic approach by analyzing endothelial cell-surface membrane proteins </plain></SENT>
<SENT sid="4" pm="."><plain>Sera from SN-APS patients revealed 2 reactive spots corresponding to vimentin, a protein that is shown to bind <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>Antivimentin/<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies were tested in 29 SN-APS patients, 40 APS patients, 30 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, 30 with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, 30 with venous or <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, and 32 healthy control patients </plain></SENT>
<SENT sid="6" pm="."><plain>We observed that not only a large proportion of SN-APS patients but also almost <z:hpo ids='HP_0000001'>all</z:hpo> the APS patients displayed the presence of antivimentin/<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies </plain></SENT>
<SENT sid="7" pm="."><plain>To verify the possible pathogenic role of these autoantibodies, we demonstrated that affinity-purified antivimentin/<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies induced interleukin receptor-associated kinase phosphorylation and nuclear factor-ÎºB activation in endothelial cells </plain></SENT>
<SENT sid="8" pm="."><plain>Our results prompt to identify vimentin as a "new" cofactor for aPL, which may represent a useful tool mainly in SN-APS patients </plain></SENT>
</text></document>